| Israele | Turchia | Austria | |
| Immunoterapia del sarcoma | - | da $18,000 | da $60,000 |
Bookimed non aggiunge costi extra ai prezzi di Immunoterapia del sarcoma. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica per la tua Immunoterapia del sarcoma al tuo arrivo.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali in Immunoterapia del sarcoma e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di Immunoterapia del sarcoma.
Il Prof. Merimsky guida l'Unità di Oncologia dei Tessuti Molli e delle Ossa presso il Centro Medico Sourasky, specializzandosi nell'immunoterapia dei sarcomi con oltre 25 anni di esperienza mirata.
Dr. Ronit El Hasid is the Head of Pediatric Oncohematology and Oncology at Dana Dwek Children’s Hospital (Sourasky). She specializes in bone marrow and umbilical blood transplantation and has conducted over 300 transplantations and published 50 papers and 40 reports. She is a member of American Association for Hematology and Israeli Society for Pediatric Hematooncology, and has previously practiced in the City of Hope Hospital (Los-Angeles) and other medical centers in Israel.
Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.
Dr. Michael Lotem leads the Melanoma and Cancer Immunotherapy Center at Hadassah Medical Center. He specializes in advanced immunotherapy for melanoma. He is known for his research on SLAM receptors and their role in anti-cancer immune responses. Dr. Lotem has published widely in leading medical journals.
He heads a multidisciplinary team that uses clinical data and patient samples to advance research. Under his leadership, the center has improved patient outcomes with new therapies. The center is now recognized as a leader in cancer immunotherapy.